Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by M. Pompen
Pcn190 - Cost-Effectiveness of Nivolumab + Ipilimumab in First-Line Treatment of Advanced or Metastatic Renal Cell Carcinoma in the Netherlands
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Effectiveness of Dapagliflozin as Add-On to Insulin for the Treatment of Type 2 Diabetes in the Netherlands
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Cost-Effectiveness of Nivolumab in Combination With Ipilimumab in First-Line Treatment of Advanced Melanoma in Sweden
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn136 - A Cost-Effectiveness Analysis of Nivolumab in Combination With Ipilimumab for the Treatment of Advanced Renal Cell Carcinoma in Canada
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Effectiveness Analysis of Sunitinib Versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore
International Journal of Technology Assessment in Health Care
Health Policy
Nivolumab in the Treatment of Advanced Renal Cell Carcinoma
Oncology in Clinical Practice
Oncology
Pcn184 - Cost-Effectiveness of Nivolumab Plus Ipilimumab in Advanced Melanoma
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn94 - Cost-Effectiveness of Cabozantinib Versus Sunitinib or Pazopanib as First-Line Treatment of Patients With Advanced Renal Cell Carcinoma in the Uk
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn185 - Cost-Effectiveness of Nivolumab in Second-Line Treatment of Locally Advanced Unresectable or Metastatic Urothelial Carcinoma in Adults After Failure of Prior Platinum-Containing Therapy in Greece
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Clinical Cancer Research
Cancer Research
Oncology
Cost-Effectiveness and Cost-Utility Analysis of Sunitinib Versus Sorafenib and Bevacizumab + Interferon-Alfa as First-Line Treatment for Metastatic Renal Cell Carcinoma in Ecuador
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
